Skip to main content

Advertisement

Table 2 Individual SpA subject characteristics

From: Insights in to the pathogenesis of axial spondyloarthropathy based on gene expression profiles

Subject Dataset Gender Race SpA Likelihood ratio Medications
1 1 M Asian 4073 None (Etanercept withdrawn for 2 months)
2* 1 M Caucasian 204 Simvastatin, cyclobenzaprine, aspirin, indomethacin, atenolol, lansoprazole, hydrocodone
3 1 M Caucasian 204 _
4 1 M Caucasian 4073 _
5 1 M Caucasian 934 _
6 1 M Asian 204 _
7 1 M Caucasian 4073 Metformin, glipizide, atorvastatin, lisinopril, nifedipine, Lantus insulin, Novo Log, sulfasalazine, indomethacin
8 1 M Caucasian 558 Ibuprofen
9 1 F Caucasian 11383 Piroxicam, indomethacin
10 1 F Caucasian 7115 Rofecoxib
11 1 M Caucasian 255 Acetaminophen, ramipril, omeprazole, aspirin, atorvastatin
12 2 M Caucasian 4073 Insulin, nifedipine, glipizide, lisinopril, metformin, Vicodin, Flexeril, indomethacin, sulfasalazine
13 2 F Caucasian 1039 Celecoxib, trazodone, venlafaxine, ranitidine
14 2 F Caucasian 204 Tobramycin
15 2 F Asian 4073 Alendronate
16 2 M Asian 204 _
17 2 M Caucasian 20774 Phenylbutazone
18 2 M Caucasian 2308 Alendronate sodium
  1. *coexistent ulcerative colitis. F = female; M = male; SpA = axial spondyloarthropathy.